XML 61 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Investment in Associate (Tables)
12 Months Ended
Dec. 31, 2022
VISEN Pharmaceuticals [member]  
Disclosure of associates [line items]  
Schedule of Financial Information of Investment in VISEN

The following table illustrates the summarized relevant financial information of VISEN:

 

 

VISEN Pharmaceuticals

 

Principal place of business

 

China

 

 

 

2022

 

 

2021

 

 

 

(EUR’000)

 

Statement of profit or loss

 

 

 

 

 

 

Profit/(loss) for the year from continuing operations

 

 

(40,283

)

 

 

(69,283

)

Total comprehensive income

 

 

(40,273

)

 

 

(69,306

)

Statement of financial position

 

 

 

 

 

 

Non-current assets

 

 

21,410

 

 

 

16,599

 

Current assets

 

 

92,204

 

 

 

130,825

 

Total assets

 

 

113,614

 

 

 

147,424

 

Equity

 

 

100,062

 

 

 

135,333

 

Non-current liabilities

 

 

180

 

 

 

1,545

 

Current liabilities

 

 

13,372

 

 

 

10,546

 

Total equity and liabilities

 

 

113,614

 

 

 

147,424

 

Company’s share of equity before eliminations

 

 

43,957

 

 

 

59,455

 

Elimination of internal profit and other equity method adjustments

 

 

(21,025

)

 

 

(21,110

)

Company’s share of equity

 

 

22,932

 

 

 

38,345

 

Investment in associate at December 31

 

 

22,932

 

 

 

38,345

 

Present ownership at December 31

 

 

43.93

%

 

 

43.93

%

Transactions and outstanding balances as of December 31

 

 

 

 

 

 

Invoicing of goods and services to associate

 

 

22,327

 

 

 

6,472

 

Trade receivables from associate

 

 

3,554

 

 

 

1,644